Spyre Therapeutics, Inc. (SYRE) Presents at Leerink Global Healthcare Conference 2026 Transcript

Core Insights - Spyre Therapeutics is positioned to leverage the rise of combination therapies in inflammatory bowel disease and has potential in rheumatology with TL1A [2] - The company is expected to release significant data over the next nine months, with six Phase II readouts scheduled for this year [2] Company Overview - The management team of Spyre Therapeutics includes CEO Cameron Turtle and CMO Sheldon Sloan [1] - The company is actively investigating its therapeutic hypotheses in both inflammatory bowel disease and rheumatology [2]